Eli Lilly Q1 2026: Revenue Surges 56% as GLP-1 Boom Deepens
Eli Lilly beat Q1 2026 estimates with $19.8B revenue (+56%), EPS of $8.26 (+170%), driven by Mounjaro, Zepbound, and newly launched oral pill Foundayo.
Eli Lilly beat Q1 2026 estimates with $19.8B revenue (+56%), EPS of $8.26 (+170%), driven by Mounjaro, Zepbound, and newly launched oral pill Foundayo.
NXP Semiconductors surged 26% — its best day since listing in 2010 — as Q1 earnings beat estimates and Q2 guidance of up to $3.55B signaled a chip recovery led by auto and AI.
Learn how options work — what calls and puts are, how premiums are priced, and the difference between intrinsic and extrinsic value. Includes payoff diagrams.
Meta, Alphabet, Amazon, and Microsoft posted Q1 2026 earnings beats this week—combined revenues hit $430 billion as AI investments begin delivering measurable results across the board.
Bloom Energy (BE) surges 23% after Q1 2026 revenue jumps 130% to $751M on AI data center demand; full-year revenue guidance raised to $3.4B–$3.8B.
Coca-Cola reported $12.47B in Q1 2026 revenue — up 12% year-over-year — and raised its full-year profit forecast, sending KO shares up 3.86% on the session.
Apple reports Q2 FY2026 earnings April 30 with analysts expecting $108.9B in revenue and $1.93 EPS. Key themes: Services momentum, AI-driven iPhone upgrades, and tariff headwinds.
Spotify stock fell 13% after Q1 2026 results as soft Q2 subscriber and profit guidance overshadowed a strong profit beat and 40% operating income growth.
General Motors reports Q1 2026 after the bell April 28. Here’s what analysts expect—and why tariffs are the key wildcard for the stock and Detroit’s entire supply chain.
Nucor crushed Q1 2026 estimates — EPS $3.23 vs. $2.82 expected, revenue up 21% to $9.5B — as Section 232 tariffs and AI infrastructure demand power a historic earnings rebound.